Gold medal to Belorussian State University for development and marketing of Temodex
Belorussian State University has in 2015 received a 1-st grade Diploma and a gold medal at RESTEC® HiTech exhibition forum in St. Petersburg for the development of Temodex – pharmaceutical formulation for local chemotherapy treatment of brain tumours. The prize was received in the category “Best Innovation Project: successful product marketing, best manufacturing, best stock handling and best logistics”.
Temodex, which is a locally acting form of temozolomide, was developed by the Research Institute of Physical and Chemical Preparations at Belorussian State University in Minsk, Belarus, and has successfully been tested in clinical trials. Temodex is registered as a first line treatment of glioblastoma in Belarus since 2014. For more info: http://doublebp.com/index.php/temodex
Temozolomide - a imidazotetrazine derivative of the alkylating agent dacarbazine - is an oral chemotherapy drug which is considered to be a prodrug. Temozolomide is used as a treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for glioblastoma. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. Temozolomide was developed by Malcolm Stevens and his team at Aston University in Birmingham in UK and has been available in the US since year 1999, and in other countries since year 2000.
Glioblastoma is the most common and aggressive malignant form of all primary brain tumors. It affects glial cells and accounts for 52% of all brain tissue tumor cases and 20% of all tumors inside the skull. About 50% of the patients diagnosed with glioblastoma die within one year, and 90% - within three years.
Company name: Double Bond Pharmaceutical International AB
Corporate identity number: 556991-6082
Stock short name: DBP B
ISIN code: SE0007185525
Information about Double Bond Pharmaceutical International AB:
DBP is a pharmaceutical company that primarily develops drugs against cancer through its proprietary drug delivery technology. The company was granted Orphan Drug status by the European Medicines Agency in June 2015 for its first product, SA033, for treatment of hepatoblastoma.